This is a routine board appointment with no financial or strategic catalyst. Monitor next quarterly filing for any guidance updates or commercial progress on LYMPHIR, which is the company's primary value driver.
Price Chart
Executive Summary
Citius Oncology appointed Jonathan Peri, Ph.D., J.D., as an independent Class I director, expanding the board to nine members. This is a routine governance addition with no financial terms disclosed and no departure of existing officers, making it a neutral event with minimal immediate trading implications.
Key Facts
- Board expanded to nine members with the appointment of Jonathan Peri as an independent Class I director, effective August 10, 2026.
- Dr. Peri serves until the 2028 annual meeting and will be compensated under the company's independent director program, currently under review.
- No departures, officer changes, or material financial data were disclosed in the filing.
Financial Impact
No financial impact disclosed; director compensation is routine and immaterial.
Risk Factors
- No new risks identified from this filing; the company's existing commercial execution risk on LYMPHIR remains unchanged.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-088068 |
| Document: ea030145601ex99-1.htm | 0001213900-26-088068 |
| Document: 0001213900-26-088068-index-headers.html | 0001213900-26-088068 |
| Document: 0001213900-26-088068-index.html | 0001213900-26-088068 |
| Document: 0001213900-26-088068.txt | 0001213900-26-088068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.6000 | awaiting T+5 | — | $0.5957 (−0.72%) |
Oct 26, 2026 today | Press Release | $0.6072 | awaiting T+5 | — | $0.5957 (−1.89%) |
Oct 23, 2026 3d ago | 8-K | $0.5795 | awaiting T+5 | — | $0.5957 (−2.80%) |
Aug 12, 2026 10w ago | 8-K | $0.8115 $0.7525 | ▼ −7.27% | ▼ −6.83% | $0.5957 (−26.59%) |
Aug 5, 2026 11w ago | 8-K | $0.7850 $0.8115 | ▲ +3.38% | ▲ +3.03% | $0.5957 (−24.11%) |
Jun 8, 2026 20w ago | EFFECT | $0.7999 $0.6802 | ▲ +14.96% | ▲ +17.08% | $0.5957 (+25.53%) |
Jun 1, 2026 21w ago | 8-K | $0.7830 $0.7200 | ▼ −8.05% | ▼ −5.08% | $0.5957 (−23.92%) |
May 29, 2026 21w ago | S-3 | $0.7920 $0.7800 | ▲ +1.52% | ▼ −1.24% | $0.5957 (+24.79%) |
May 15, 2026 23w ago | 8-K | $0.8290 $0.8600 | ▲ +3.74% | ▲ +2.12% | $0.5957 (−28.14%) |
Mar 3, 2026 33w ago | EFFECT | $1.06 $1.01 | ▼ −5.19% | ▼ −4.71% | $0.5957 (−43.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers